TICKERNERD
Menu
BSEMBSEMHealthcare · Biotechnology

BSEM Stock Forecast: BioStem Technologies, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$2.76
+0.92% on the day

The 1 Wall Street analysts covering BioStem Technologies, Inc. hold a median 12-month price target of $7 — +154.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$51.4M
Ticker Nerd rank
57 / 100
Median analyst target
$7.00
Analysts covering
1
Revenue$7.9M−57.1% y/y
Operating income−$8.4M
Net income−$9.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−32.0%
1M
−25.7%
YTD
−27.7%
1Y
−44.4%
From 52W high
−66.4%
From 52W low
+0.9%
$2.73
$8.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BSEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioStem Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Revisions
84
Size
82
Issuance
69
Quality
55
Value
32
Momentum
25
Volatility
10
Growth
9

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BSEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BSEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26BSEMHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $7.00Median $7.00High $7.00

The green dot is the last close — the median target sits +154.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Nov 2022Zacks Investment ResearchInitiatesBuy$6.40
7 Nov 2022Zacks Investment ResearchInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BSEM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BSEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, BioStem Technologies, Inc. returned −44.4% against +17.0% for the S&P 500, dividends included.

BSEM vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26BSEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BSEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

BioStem Technologies, Inc. (BSEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.1×

Cheaper than 68% of US stocks

Price / sales
1.5×

Cheaper than 59% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−2.0×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−27.9%

Higher than 9% of US stocks

Earnings growth (YoY)
−57.1%

Higher than 9% of US stocks

Gross margin
61.3%

Higher than 74% of US stocks

Operating margin
−106.3%

Higher than 13% of US stocks

Net margin
−81.8%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−74.7%

Higher than 17% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioStem Technologies, Inc. (BSEM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioStem Technologies, Inc. has a market value of $51.4M and an enterprise value of $43.4M.

  • Revenue in the twelve months to 30 June 2026: $132.2M. The latest quarter shrank 27.9% year on year.

  • Net income over the same four quarters: $7.3M, a 5.5% net margin.

  • Shares outstanding: 17.8M.

  • Trailing P/E: 3.1×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioStem Technologies, Inc. employs 73 people — $1.8M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

BSEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BSEMBioStem Technologies, Inc.$51.4M
57
TILInstil Bio, Inc.$49.0M
37
DWTXDogwood Therapeutics, Inc.$49.6M
38
SERSerina Therapeutics, Inc.$49.8M
19
ANVSAnnovis Bio, Inc.$50.2M
27
ELTXElicio Therapeutics, Inc.$50.5M
38
INMBINmune Bio, Inc.$51.3M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioStem Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BSEM news & analysis

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

GlobeNewsWire · 1 Oct 2026positive

BioStem Technologies announced that the USPTO issued one patent and three notices of allowance, and the Mexican Institute of Industrial Property issued one notice of allowance, all related to its placental allograft and umbilical tissue patent portfolio.

Why it matters — This strengthens BioStem's intellectual property protection for its perinatal tissue allograft products in both US and Mexican markets.

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewsWire · 30 Sept 2026neutral

BioStem Technologies announced it has entered into definitive agreements for a $3 million private placement, issuing 735,296 shares of common stock alongside Series A and Series B warrants for an additional 735,296 shares each, priced at $4.08 per share at-the-market under Nasdaq rules.

Why it matters — This private placement represents new equity and warrant financing for the regenerative medicine company, which could affect share count and available capital for BSEM watchers.

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

GlobeNewsWire · 21 Sept 2026neutral

Terminal1, an operating system built for public companies, announced that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined its platform. The announcement was made via GlobeNewswire on September 21, 2026.

Why it matters — The announcement indicates BioStem Technologies has adopted a new corporate operating platform, which may be of interest to those tracking the company's operational infrastructure and technology choices.

BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility

GlobeNewsWire · 18 Sept 2026positive

BioStem Technologies announced it has entered into a $40 million Committed Equity Facility (CEF) with Roth Principal Investments, LLC, an affiliate of CR Financial Holdings. The facility, announced on September 18, 2026, provides up to $40 million in committed capital to the regenerative medicine company.

Why it matters — The committed equity facility provides BioStem with access to additional capital, which could support its development and commercialization efforts.

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

GlobeNewsWire · 4 Sept 2026positive

BioStem Technologies announced that its VENDAJE® and VENDAJE AC® products have been added to the Company's existing contracts with Vizient Inc. and Premier Inc., two of the nation's largest Group Purchasing Organizations, expanding hospital access for the products.

Why it matters — Inclusion in these major GPO contracts could broaden hospital purchasing access to VENDAJE and VENDAJE AC, potentially supporting commercial reach for BioStem's perinatal tissue allograft products.

FAQ

Frequently asked questions about BSEM stock

What is the BSEM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering BioStem Technologies, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BSEM stock a buy right now?

Of the 1 analysts covering BioStem Technologies, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioStem Technologies, Inc. 57 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BSEM?

As at 3 Oct 2026, BioStem Technologies, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will BSEM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +154.1% from the last close, and Ticker Nerd's factor model ranks BioStem Technologies, Inc. 57 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BSEM stock forecast for 2030?

No analyst covering BioStem Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has BSEM stock performed over the past year?

BioStem Technologies, Inc. returned -44.4% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioStem Technologies, Inc. do?

BioStem Technologies Inc. is a biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies.

What is the latest news on BSEM?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio". BioStem Technologies announced that the USPTO issued one patent and three notices of allowance, and the Mexican Institute of Industrial Property issued one notice of allowance, all related to its placental allograft and umbilical tissue patent portfolio.

Company

About BioStem Technologies, Inc.

BioStem Technologies Inc. is a biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies. BioStem Technologies Inc. provides tissue-based solutions used in surgical and wound care settings, with products designed to support soft tissue coverage and repair. Its portfolio includes structural tissue allografts and human connective tissue matrices such as Vendaje, Vendaje AC, Vendaje OPTIC, American Amnion, and American Amnion AC. The company also uses its proprietary BioRetain processing method to preserve the natural properties of perinatal tissue while producing its biologic products. BioStem Technologies Inc. serves clinicians and healthcare providers across specialties where tissue repair and regenerative medicine are used, making it a specialized player in the biologics and wound care market.

CEO Mr. Jason V. Matuszewski · 73 employees · United States · https://biostemtechnologies.com